ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Description

Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting

Conditions

Bladder Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Condition
Bladder Cancer
Intervention / Treatment

-

Contacts and Locations

Gilbert

Ferring Investigational Site, Gilbert, Arizona, United States, 85234

Little Rock

Ferring Investigational Site, Little Rock, Arkansas, United States, 72211

Fresno

Ferring Investigational Site, Fresno, California, United States, 93720

Los Angeles

Ferring Investigational Site, Los Angeles, California, United States, 90033

Gainesville

Ferring Investigational Site, Gainesville, Florida, United States, 32608

Atlanta

Ferring Investigational Site, Atlanta, Georgia, United States, 30328

Greenwood

Ferring Investigational Site, Greenwood, Indiana, United States, 46143

Jeffersonville

Ferring Investigational Site, Jeffersonville, Indiana, United States, 47130

Wichita

Ferring Investigational Site, Wichita, Kansas, United States, 67226

Baltimore

Ferring Investigational Site, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Prescribed and scheduled treatment with ADSTILADRIN per physician discretion or received the first instillation of ADSTILADRIN per physician discretion after 5 September 2023 but prior to site activation
  • * Signed and dated ICF.
  • * Age 18 years or older at day ICF is signed.
  • * Currently enrolled in a clinical trial.
  • * Participants who have previously been treated with ADSTILADRIN in the context of a clinical trial
  • * Participant is pregnant or breastfeeding.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ferring Pharmaceuticals,

Global Clinical Compliance, STUDY_DIRECTOR, Ferring Pharmaceuticals

Study Record Dates

2025-12-31